Novo Nordisk (NYSE:NVO), a leading global pharmaceutical company based in Denmark, is renowned for its advancements in diabetes care and hormone replacement therapies. The company competes with other pharmaceutical giants such as Eli Lilly and Sanofi. On August 13, 2025, Exane BNP Paribas upgraded NVO's stock from "Underperform" to "Neutral," with the stock priced at $49.78 at the time.
This upgrade occurs amidst ongoing legal challenges for Novo Nordisk. Berger Montague PC is investigating claims under federal securities laws against the company. A class action lawsuit has been filed, targeting investors who acquired Novo securities between May 7, 2025, and July 28, 2025. These investors have until September 30, 2025, to seek appointment as lead plaintiff representatives.
The lawsuit follows Novo Nordisk's announcement on July 29, 2025, where the company lowered its sales and profit guidance for the second half of fiscal 2025. This adjustment was due to the persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products, Wegovy® and Ozempic®. Consequently, the stock price dropped from $69.00 to $53.94, a one-day decline of over 21%.
Currently, NVO's stock price is $49.78, reflecting a slight decrease of 0.18% or $0.09. The stock has traded between $49.38 and $50.31 today. Over the past year, it reached a high of $139.74 and a low of $45.05. NVO has a market capitalization of approximately $223.3 billion, with a trading volume of 10,468,598 shares.
